The European Association for the Study of Obesity published its 2026 framework update in Nature Medicine on May 12, and the headline is straightforward: for pure weight loss in uncomplicated obesity, tirzepatide now sits above semaglutide in the clinical algorithm. But the full picture is more nuanced than the headline suggests — and which compound is "better" depends entirely on what you are optimizing for.
What the EASO 2026 Framework Actually Says
The updated framework is a living pharmacotherapy algorithm that maps obesity medications to specific clinical domains: body weight management, MASH (metabolic dysfunction-associated steatohepatitis) resolution, liver fibrosis improvement, cardiovascular risk reduction, and type 2 diabetes management. It was presented at the 33rd European Congress on Obesity in Istanbul and published simultaneously in Nature Medicine (PMID: 42120724).
Three changes matter most:
1. Tirzepatide ranks above semaglutide for weight loss. This is based primarily on SURMOUNT-5, the first head-to-head Phase 3b trial. At 72 weeks, tirzepatide produced 20.2% body weight reduction versus 13.7% for semaglutide (NEJM 2025; doi:10.1056/NEJMoa2416394). The gap was consistent across subgroups — tirzepatide won on waist circumference, percentage achieving 25%+ loss, and GI tolerability (fewer dropouts from side effects).
2. MASH and fibrosis are now separate domains. The 2025 version of the algorithm treated liver disease as one bucket. The 2026 update splits it into MASH resolution (where both semaglutide and tirzepatide have evidence) and liver fibrosis improvement (where semaglutide stands alone). This reflects the ESSENCE Phase 3 trial, in which semaglutide 2.4 mg achieved MASH resolution in 62.9% of patients and fibrosis improvement in 36.8% — both significantly above placebo (NEJM 2025; doi:10.1056/NEJMoa2413258).
3. Cardiovascular positioning did not change. Semaglutide remains the only GLP-1 with a dedicated, positive cardiovascular outcomes trial in obesity without diabetes. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (NEJM 2023;389:2221-32). Tirzepatide's SURPASS-CVOT showed non-inferiority to dulaglutide in type 2 diabetes, but there is no head-to-head cardiovascular trial versus semaglutide in an obesity-only population.
What This Means for Buyers
The EASO framework is not a prescribing mandate — the authors explicitly state it "should not be viewed as a universal ranking." But it is the most evidence-dense decision tool available for matching a specific patient profile to a specific GLP-1 compound. Here is how to read it:
If your primary goal is maximum weight loss and you have no significant cardiovascular history or liver disease: tirzepatide is the stronger evidence pick. SURMOUNT-5 is the only head-to-head trial, and tirzepatide won by roughly 7 percentage points — a clinically meaningful gap that translates to approximately 7.8 kg (17 lb) of additional weight lost over 72 weeks.
If you have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) without diabetes: semaglutide has the deeper evidence base. The SELECT trial enrolled 17,604 patients and ran for a median of 39.8 months. There is nothing comparable for tirzepatide in this specific population.
If fatty liver disease (MASH with fibrosis) is a concern: the ESSENCE trial positions semaglutide as the frontrunner for fibrosis improvement. Tirzepatide has Phase 2 MASH data (the SYNERGY-NASH trial) but lacks a completed Phase 3 readout in this indication.
For most research peptide buyers weighing cost, access, and outcome: the practical gap may be narrower than the framework suggests. Both compounds produce substantial weight loss, both suppress appetite through overlapping GLP-1 receptor mechanisms, and both are available from verified US research vendors. The 7-point weight-loss gap favoring tirzepatide is real but diminishes if cardiovascular or liver endpoints also matter to you.
Current vendor pricing for both compounds is tracked on our best tirzepatide vendors and best semaglutide vendors pages.
